NBIX

Business Context and Reporting Period

Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2000
Business Overview: Neurocrine is a product-based biopharmaceutical company focused on neurologic and endocrine diseases. The company has no product sales revenue; it funds operations through equity offerings and strategic collaborations with major pharmaceutical companies (e.g., Janssen, Wyeth-Ayerst, Taisho, Eli Lilly). The pipeline includes 15 programs, with five in clinical development targeting insomnia, anxiety, depression, cancer, and diabetes.

Key Financial Metrics (Year Ended Dec 31, 2000)

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 13% to $14.6 million from $16.8 million in 1999. This was primarily due to the conclusion of the Novartis collaboration (January 2000) and the sponsored research portion of the Eli Lilly agreement (October 1999). These losses were partially offset by $7.1 million in revenues from a new collaboration with Taisho Pharmaceuticals.
• Increased Operating Loss: Net loss widened to $28.8 million (from $16.8 million in 1999) driven by a 38% increase in R&D expenses ($40.2 million) as drug candidates advanced into later clinical phases, and a 33% increase in General and Administrative expenses ($10.0 million) due to business development consulting and stock compensation.
• Liquidity Expansion: Cash and short-term investments increased significantly to $164.7 million (from $91.1 million) following a December 2000 public offering that generated $90.4 million in net proceeds.
• Accounting Change: Adoption of SAB 101 in Q4 2000 required the deferral of $4.2 million in license fees, increasing the reported net loss by approximately $3.8 million for the year.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur operating losses for the foreseeable future as clinical development costs rise. The company anticipates spending approximately $35 million in 2001 on clinical testing for its insomnia and brain cancer compounds.
• Liquidity: Management believes existing capital resources, combined with interest income and future collaboration payments, are sufficient to meet funding requirements for at least the next 12 months.
• Key Risks:
  • Clinical Failure: Product candidates may fail to demonstrate efficacy or safety in future trials (e.g., Janssen discontinued one CRF R1 candidate due to liver enzyme issues, though a backup is in development).
  • Collaboration Dependence: Revenue is heavily reliant on milestone payments and sponsored research from partners; termination of these agreements (as seen with Novartis) causes revenue volatility.
  • Regulatory Uncertainty: No products have been approved; the company faces the lengthy and expensive process of FDA approval.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $164.7 million cash balance against the projected $35 million+ R&D spend for 2001 and future capital needs.
• Collaboration Terms: Review the specific milestone triggers and payment schedules for the Taisho, Janssen, and Wyeth-Ayerst agreements to assess future revenue visibility.
• Clinical Trial Status: Monitor the progress of Phase II/III trials for NBI-34060 (insomnia) and NBI-3001 (malignant glioma), as these are the most advanced assets.
• Accounting Adjustments: Confirm the amortization schedule for the $4.2 million in deferred license fees recognized under SAB 101.